Amgen Inc. $AMGN Shares Acquired by KMG Fiduciary Partners LLC

Key Points

• KMG Fiduciary Partners increased its Amgen stake by 38.9% in the second quarter, bringing its holdings to 9,856 shares valued at approximately $3.57 million. Institutional investors collectively own 76.5% of Amgen.
• Amgen reported a quarterly earnings beat, with EPS of $6.29 versus the $5.62 consensus and revenue of $10.05 billion, up 9.5% year over year. The company reaffirmed fiscal 2026 EPS guidance of $22.30–$23.50.
• Analyst opinions remain mixed, producing a consensus “Hold” rating and a $371.68 price target, while Amgen’s $2.52 quarterly dividend implies an annualized yield of 2.4%.

KMG Fiduciary Partners LLC grew its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 38.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 9,856 shares of the medical research company's stock after purchasing an additional 2,758 shares during the period. KMG Fiduciary Partners LLC's holdings in Amgen were worth $3,569,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Dogwood Wealth Management LLC raised its stake in Amgen by 275.0% in the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company's stock valued at $25,000 after buying an additional 55 shares during the last quarter. Anfield Capital Management LLC grew its stake in shares of Amgen by 1,000.0% during the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company's stock worth $25,000 after acquiring an additional 70 shares during the last quarter. Tower View Wealth Management LLC grew its stake in shares of Amgen by 331.6% during the first quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company's stock worth $29,000 after acquiring an additional 63 shares during the last quarter. Manning & Napier Advisors LLC increased its holdings in shares of Amgen by 49.2% during the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company's stock valued at $32,000 after acquiring an additional 32 shares in the last quarter. Finally, Ares Financial Consulting LLC purchased a new position in shares of Amgen in the 4th quarter valued at approximately $34,000. Institutional investors and hedge funds own 76.50% of the company's stock.

Analysts Set New Price Targets

A number of research firms recently commented on AMGN. Morgan Stanley lifted their target price on shares of Amgen from $333.00 to $351.00 and gave the stock an "equal weight" rating in a research note on Wednesday, August 5th. BMO Capital Markets upped their price target on shares of Amgen from $400.00 to $450.00 and gave the company an "outperform" rating in a research note on Wednesday, August 5th. Piper Sandler reaffirmed an "overweight" rating on shares of Amgen in a report on Friday, June 12th. Argus dropped their price objective on shares of Amgen from $400.00 to $375.00 and set a "buy" rating on the stock in a report on Wednesday, May 20th. Finally, The Goldman Sachs Group set a $389.00 target price on Amgen in a research report on Friday, June 5th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, fifteen have issued a Hold rating and three have given a Sell rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $371.68.

Amgen Price Performance

Shares of NASDAQ AMGN opened at $417.20 on Tuesday. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13. The stock has a market capitalization of $225.55 billion, a price-to-earnings ratio of 25.93, a PEG ratio of 3.82 and a beta of 0.41. The firm's 50 day simple moving average is $364.54 and its 200-day simple moving average is $357.03. Amgen Inc. has a 12 month low of $269.77 and a 12 month high of $418.40.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The firm had revenue of $10.05 billion during the quarter, compared to analysts' expectations of $9.43 billion. During the same period in the previous year, the business posted $6.02 EPS. The business's revenue was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Analysts expect that Amgen Inc. will post 22.78 EPS for the current year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 21st will be given a $2.52 dividend. The ex-dividend date is Friday, August 21st. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.4%. Amgen's dividend payout ratio is 62.65%.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 2,970 shares of the stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the sale, the senior vice president directly owned 7,340 shares of the company's stock, valued at $2,951,854.40. This represents a 28.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 0.85% of the company's stock.

About Amgen

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source